CTSO - Company ID 0001175151
The table below shows Cytosorbents Corp's income statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $37.06M | $35.59M | $31.08M | $34.69M | $43.17M | $41.00M |
| Cost of revenue | $10.57M | $10.71M | $9.13M | $13.96M | $11.05M | $11.05M |
| Gross profit | $26.49M | $24.89M | $21.95M | $20.73M | $32.12M | $29.95M |
| R&D | - | - | $15.73M | $15.12M | $16.38M | $8.81M |
Cytosorbents Corp reported annual revenue of $37.06M for fiscal year 2025. That is up 4.1% from $35.59M in fiscal 2024. Over the 10 fiscal years shown, annual revenue grew from $9.53M (FY 2016) to $37.06M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| SG&A |
| $35.65M |
| $33.73M |
| $38.31M |
| $34.29M |
| $35.75M |
| $28.46M |
| Operating income | -$14.75M | -$16.45M | -$31.95M | -$31.52M | -$22.74M | -$10.37M |
| Income tax | -$401.00K | -$1.69M | -$813.74K | -$1.09M | -$736.00K | -$1.13M |
| Net income | -$8.20M | -$20.72M | -$29.25M | -$32.81M | -$24.56M | -$7.84M |
| EPS (diluted) | -$0.13 | -$0.38 | -$0.65 | -$0.75 | -$0.57 | -$0.20 |